Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
To buy 511 million that look like mostly buys ---WHO IS SUPPLYING THE SHARES ???????
It would be nice if the company would supply proof that there not selling as a kindness to thousands of beat up and bewildered stock holders over the past month or so. I am one of them that are very puzzled. Last month at .0002 I tried to sell part of my shares for weeks – not a nibble. A list- buyers to sellers ratio would be enlightening and welcome.
Who keeps buying @.0001 – why doesn’t the price go up with so much volume and who’s selling at .0001
ARIA
To find tomorrow's winners, we've enlisted the help of more than 140,000 monster trackers at Motley Fool CAPS. Tomorrow's Monster Stock?Stocks climbing to 10 times their original price
http://www.fool.com/investing/high-growth/2009/09/04/tomorrows-monster-stock.aspx
Is it possible to sell even at .0001?
About a month or so back when the price was, 0002 I tried selling some for weeks and not a nibble with high vol. very confusing. Who is buying under the bid? How do they do that? HOW is there always such HIGH VOL? is EVFL buy back stock-- A little light???
Is it possible to sell even at .0001?
Just arrivied, I hold 1,400,000 shares EVFL and I’m$230. red ink, any real understanding of a turn around? Price? Time frame?
Wild reality could easily become $20 to $ 40 if they pass FDA
Where is SPPI going from here$?Anyone following ARIA?
Ariad Pharmaceuticals (ARIA)
The folks at ARIA are scheduled to release the first interim analysis from a Phase 3 study of their cancer drug ridaforolimus (rida) on or before September 30. Rida is indicated for rare soft tissue and bone sarcomas. The company expects to provide the results from a second interim analysis in Q1 2010 or no later than March 31, 2010. With positive results from the second interim analysis, the company will file an NDA requesting early approval for the drug. If granted priority review from regulators, then rida could be approved as early as Q4 2010.
Like ALTH’s drug PTX, ARIA’s rida is also an orphan drug. Unlike ALTH, however, ARIA has a collaboration agreement with Merck (MRK), which is valued at or near $1 billion. For more details on ARIA, please refer to this
Please refer to this September 01, 2009
http://seekingalpha.com/article/159255-five-drug-makers-with-pending-catalysts?source=yahoo
Anyone have any idea whats going on?
I love green bars
http://www.pharmacychoice.com/news/article.cfm?Article_ID=448294
8/31/09 - American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device
2009 AUG 31 - (NewsRx.com) In keeping with its mission to provide unique products that greatly benefit the wellbeing of families, American Scientific Resources (the Company) (Pink Sheets: ASFX), announced it has obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell and market home Needle Destruction Devices (NDD) known as the Disintegrator? and the Disintegrator Plus? (see also American Scientific Resources, Inc.).
All current and future sales and contracts worldwide have been granted to the Company.
This is GOOD! Keep the Dialogue going!!!
doggone-- Why is ASFX willing to spend a dime toward the purchase of this patent and why did the FDA bother to be a part of YOUR theoretical scheme. And just maybe the “larger and more reputable companies than ASFX” Blinked and it got snatched from under their noses.
TDA let me into ASFX and has ASFX listed to now sell
WHY is it “none of us are able to sell at 0.0002” I listed some at 0.0002 for 2 weeks and not a nibble with large vol. every day?
I just tuned in and very confused on what is going on. Is Exxon going to buy Evfl? Should we be holding tight on our shares? Are we going up ($) or down? What price is the common thinking? Thank you in advance to whoever fills me in.
Can someone please explain to me how, at 12:56 pm today 22,000 shares where picked up @ 0.01 per share????
AlphaRx and Venturepharm Announce Collaboration Agreement
PR Newswire
posted: 18 HOURS 29 MINUTES AGOMARKHAM, ON, Aug. 4 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTC BB:ALRX.OB - News), an emerging biopharmaceutical company utilizing proprietary drug delivery technology to develop novel formulations of drugs, today announced that the Company has entered into a collaboration agreement with Venturepharm Group (the "Venturepharm") to establish a drug development center in China Medical City, Taizhou, China that is expected to be used as a platform for the development of innovative drug products for the fast growing China pharmaceutical market. The goal of this is to enhance the Company's research capabilities, expedite the development of new products as well as to expand the Company's product range.
Under the terms of the agreement, AlphaRx will incorporate its China R D facility into Venturepharm's state of the art pre-clinical development complex which comprises of a 200,000 sq. ft. chemistry center, a 200,000 sq. ft. multi-product pilot plant to support pilot scale formulation and Clinical Trial Material (CTM) manufacture of biopharmaceutical products and a 500,000 sq. ft. (Asia's largest) animal testing center (under construction). The in-house pharmaceutical research facilities provide specialized equipment for most aspects of drug research and development. AlphaRx will be responsible for all of its own product development costs and will in turn retain the intellectual property rights relating to any developed products.
Michael Lee, President of AlphaRx, said: "Venturepharm provides the equipment and physical infrastructure to further establish our presence in China and reduces our start up investment costs. As AlphaRx continues to build its presence in China, this collaboration with Venturepharm marks an important step in our overall strategy to commercialize current products and to develop new therapeutics for the world fastest growing pharmaceutical market."
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.
About Venturepharm group
Venturepharm Group is an Asia based life science leader that provides world-class, innovative, affordable and integrated service in CRO, CMO and CSO, as well as venture capital, merchant banking for the biotechnological and pharmaceutical industry. Venturepharm also engages in compound licensing, compound partnering and royalty sharing with its clients to expand the market of their products. Venturepharm conducts its business in China as well as global top five markets. The group now operates eight distinct business units with over 2500 employees worldwide.
Please, help me understand what this has to do with ALRX?
Who’s doing all the buying –someone knows something???!!!!!
Is holding good or bad – short or long term?
Ariad Pharmaceuticals, Inc. (ARIA) (JOBS) Announces Preliminary Data from Two Ongoing Clinical Trials of Its Investigational mTOR Inhibitor, Ridaforolimus, in Combination with Targeted Drugs; Says Breast Cancer Drug Shows Promise
Source: BUSINESS WIRE
Wednesday, July 29, 2009
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA - News) today announced preliminary findings from two ongoing clinical trials evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer and with bevacizumab (Avastin®) in heavily pretreated patients with refractory, metastatic solid tumors. Abstracts describing these data have been submitted for presentation at major medical meetings to be held later this year. ARIAD is developing ridaforolimus, an investigational mTOR inhibitor, in collaboration with its partner, Merck & Co, Inc
Phase 2 Clinical Trial of Ridaforolimus Combined with Trastuzumab in Metastatic Breast Cancer
There is strong preclinical evidence that resistance to trastuzumab, the mainstay of therapy for patients with Her-2 positive breast cancer, results in activation of the mTOR pathway. This ongoing Phase 2 clinical trial was designed to test the hypothesis that addition of ridaforolimus to trastuzumab in patients with metastatic breast cancer who have become resistant to trastuzumab would result in objective evidence of tumor shrinkage. All patients enrolled in the trial had documented disease progression on trastuzumab alone or in combination. Study treatment consists of oral ridaforolimus (40 mg/day, qdx5) and trastuzumab at standard doses and intervals. None of the patients received chemotherapy during the trial.
The trial started one year ago and is expected to enroll 33 patients. Fourteen sites are participating in the study. The primary objective of the study is to estimate the objective response rate (ORR) defined by RECIST criteria (complete or partial responses). According to the protocol, the study will be considered positive if at least a 15 percent ORR is achieved (five objective responses out of a total of 33 patients enrolled). Clinical-benefit response (CBR) (objective responses and durable stable disease) will also be assessed.
Key preliminary findings to date show:
Of 28 refractory patients enrolled thus far, 15 patients currently remain on study without disease progression, either with objective evidence of control of their disease or awaiting further assessment.
At least five partial responses have been observed thus far, which would meet the trial’s pre-specified criterion for a positive outcome, pending independent review of radiologic findings.
The preliminary CBR rate in these patients with progressive, refractory disease is 35 percent.
No new or unexpected safety signals due to the combination regimen were observed in the trial.
“We set a high bar for proof of concept in this trial of patients with Her-2 positive, metastatic breast cancer who have progressed while on trastuzumab treatment,” said Pierre F. Dodion, M.D., senior vice president and chief medical officer of ARIAD. “Based on preliminary assessment of the data to date, we believe that the predefined criterion for a positive outcome of the trial will be achieved. We will continue to analyze the results as we complete patient enrollment and look forward to presenting final results of the trial at a major breast cancer meeting later this year.”
Phase 1 Clinical Trial of Ridaforolimus Combined with Bevacizumab in Solid Tumors
There is strong preclinical evidence demonstrating that vascular endothelial growth factor (VEGF), the target of bevacizumab, activates the mTOR pathway through binding to VEGF receptors on endothelial cells. In addition, mTOR signaling promotes angiogenesis, and preclinical studies have demonstrated that ridaforolimus inhibits angiogenesis in addition to its effects on cancer cell growth, proliferation and metabolism.
This Phase 1 clinical trial was designed to test the hypothesis that the addition of ridaforolimus to bevacizumab in heavily pretreated patients with metastatic solid tumors who have become resistant to bevacizumab could be achieved safely and would result in evidence of clinical benefit. All patients had refractory, extensively pre-treated metastatic solid tumors (e.g., ovarian, pancreatic, colorectal, head and neck, and uterine cancers). Prior to enrollment in the current trial, all patients had received multiple regimens of chemotherapy and targeted agents, as appropriate for their tumor type, and had progressed on bevacizumab.
Patient enrollment is now complete. The primary endpoint of the study is to determine whether the standard dose of oral ridaforolimus (40 mg/day, qdx5) could be used safely in combination with each of the two approved bevacizumab dosing regimens (infusions every two or three weeks). None of the patients received chemotherapy during the trial. Seventeen patients were enrolled and treated in this study, and all are included in the analysis. Clinical anti-tumor activity was assessed using RECIST criteria.
Key preliminary results include:
Of 17 patients enrolled in the study, five patients currently remain on study without disease progression, evidence of the control of their disease.
The preliminary CBR rate in these patients with progressive, refractory disease is 35 percent.
The longest duration of stable disease currently observed in the trial is 10 cycles of therapy in a patient with advanced pancreatic cancer; this patient also had a 13 percent reduction in tumor size.
The combination of oral ridaforolimus and bevacizumab at standard doses was well tolerated. No dose-limiting toxicity of the combination was seen.
No new or unexpected safety signals due to the combination regimen were observed in the trial.
These data will be presented at the upcoming European Society of Medical Oncology (ESMO) meeting in September 2009.
“We believe that the spectrum of clinical opportunities available to us continues to broaden as we obtain new data on ridaforolimus both as a single agent and in combination with various targeted agents,” said Harvey J. Berger, M.D., chairman and chief executive officer of ARIAD. “The data from these two trials highlight the potential clinical activity of ridaforolimus in patients with difficult-to-treat, resistant and refractory cancers. Overcoming the development of drug resistance in patients with cancer represents an important challenge for new therapeutics.”
About ARIAD
ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines. The Company’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest and most urgent unmet medical need – aggressive cancers where current therapies are inadequate. ARIAD’s lead product candidate, ridaforolimus, is an investigational mTOR inhibitor in Phase 3 clinical development in patients with advanced sarcomas and is being developed in collaboration with Merck & Co., Inc. ARIAD’s second product candidate, AP24534, is an investigational multi-targeted kinase inhibitor in Phase 1 clinical development in patients with hematological cancers. ARIAD has an exclusive license to pioneering technology and patents related to certain NF-?B cell-signaling activity, which may be useful in treating certain diseases. For additional information about the Company, please visit http://www.ariad.com.
I stand corrected- jest feels like some are being hustled to sell low – stop selling cheep!!! Hold!!
Your being hustled – stop selling cheep!!!
Testing a new bottom- I wish I had additional $$ to buy more. Sold other stock but have to wait tell Wednesday for $. I will hold and ignore the day traders! This stocks has potential, don’t shoot yourself in the foot by selling cheap!
Testing a new bottom- I wish I had additional $$ to buy more. Sold other stock but have to wait tell Wednesday for $. This is one of those stocks with the potential of going to $30 or $40 conservatively. I will hold and ignore the day traders!
OK---might as well !!
Can you tell me in simple words what the up side is with this stock?
I have tried to sell shares of EVFL for over a week @ 0002 and it won’t go through. I called AMERITRADE and they said it the over the counter trader that chooses to execute a trade. Any help out there?
SpongeTech(R) Delivery Systems, Inc. Take Action to Reduce Number of Authorized Common Shares to 900 Million Shares
11:30a ET July 27, 2009 (Business Wire)
SpongeTech(R) Delivery Systems, Inc., "The Smarter Sponge(TM)", (OTCBB: SPNG) is pleased to announce that the Company is taking action to amend its Articles of Incorporation to reduce the number of common shares that the Company has authorized to 900,000,000 (nine hundred million) shares. In addition, the Company has also begun the process to lower its outstanding shares to approximately 500,000,000 (five hundred million) shares.
As reported in the Company's 8-K filing on May 26, 2009, SpongeTech(R) amended its Certificate of Incorporation to increase its authorized common shares from 1,800,000,000 (one billion, eight hundred million) to 2,000,000,000 (two billion). The increase was to provide the Company with the ability to pursue a transaction such as the acquisition of Dicon Technologies. Subsequently, the Board of Directors had approved the acquisition of Dicon Technologies which was completed on July 9, 2009 as a cash transaction, without any shares to be issued for the acquisition and without any dilution to its current shareholders; therefore enabling the Company to take action and reduce the authorized shares substantially. Furthermore, as reported in the Company's 3rd Quarter Form 10-Q filing on April 20, 2009, SpongeTech(R) had 722,866,061 shares of common stock issued and outstanding and the Company is also taking action to lower its outstanding shares by 30%. The Company's actions in this regards will include the continuation of the common stock repurchase and retirement program from the open market as well as the retiring of restricted (144R) shares of common stock currently owned by the Company and its affiliates.
"We are excited to be moving quickly to complete the process of reducing both our authorized and outstanding shares as well as provide clarity," commented Michael Metter, CEO of SpongeTech(R). "This significant reduction is an expression of both the progress that the Company and its innovative product lines have made to date. We are confident that there will be more advances to come in the near future with regards to our product development and penetration of what we fell is currently a targeted market that is extremely large, yet grossly underserved." Metter continues, "I have always commented that it is SpongeTech(R)'s commitment to shareholders to gain their trust through transparency, progress and hard work. It always has been and always will be our goal to constantly build on our shareholders confidence."
"The reduction of the Company's authorized shares is being done to assure our shareholders that we are careful and prudent with the issuance of our stock," stated SpongeTech(R)'s COO Steven Moskowitz. "The significant reduction in both the authorized as well as outstanding share structure will serve to further enhance our overall earnings per share and make our stock more attractive to own for both current as well as prospective investors."
For more information, please contact Investor Relations at 1-877-SPONGE-T, and/or visit the Company's website at: www.spongetech.com
News
BioElectronics Significantly Reduces Convertible Debt Levels CEO Provides Update on Corporate Activities
© Marketwire 2009
2009-07-24 17:17:02 -
FREDERICK, MD -- (Marketwire) -- 07/24/09 -- BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, today announce it has significantly reduced its level of convertible debt. As of the end of the June 2009 quarter, convertible debt was below $100,000 compared to approximately $910,000 as of the end of the June 2008 quarter.
Since the end of the June 2009, the balance has been reduced further.
Andrew Whelan, CEO of BioElectronics, Corp. provides the following updates on this and other corporate activities.
Convertible Debt Reduction -- We are fortunate to have now repaid almost all of our convertible debentures and we would expect the balances to be at or near zero over the coming weeks. The elimination of this type of debt is important as most institutional investors will not invest in companies with this type of debt in place. We now have a host of mainstream financing options available that offer the Company and its shareholders a significantly reduced cost of capital.
Export-Import Bank Guarantee -- With our convertible debt level reduction, we were able to secure a guarantee from the Export-Import Bank of the United States, which is the U.S. government's official export credit agency. This guarantee will make it significantly easier for us to secure lower cost capital to finance our growing international distribution network. This is a very positive development for BioElectronics.
Recent Quarterly Performance -- Later today, we will be releasing our March quarter financials with our June quarter numbers to follow over the next few weeks. While our revenues are still relatively small, we are beginning to see strong growth, particularly within our international markets -- we are clearly now moving out of the development stage. We have maintained very tight expense controls, which have enabled us to operate at a very small loss. For example, net loss in the March quarter was just under $36,000.
Margins -- We are very excited about the margins we are able to realize on our products. As will be seen in our financials, we operate at gross margins in excess of 70% even at relatively low revenue levels. As our volumes grow, we believe we may be able to meaningfully grow these already very strong margins.
Profitability Expectation -- With a growing international distribution base, probable FDA clearances coming over the next few months and very strong margins, we expect to be very profitable over the coming quarters as our business plan further develops and as our cost of capital continues to fall.
Clinical studies and Status of FDA Filings -- We will be conducting a conference call on Tuesday, July 28 to discuss the results of a clinical study recently completed under the direction of Dr. David Genecov. In addition, the management team will discuss the status of current FDA filings and the additional FDA filings we plan to make over the coming weeks. We hope you will join us for the call to discuss these exciting developments.
Our Priorities -- Our priorities in order of importance remain the following: 1) Completion of clinical studies, 2) FDA submissions, 3) International distribution expansion, and 4) Further development our patented, drug free ActiPatch, Allay and RecoveryRx brands. Reverse stock splits or reverse mergers are not being contemplated.
NEWS---
BIEL
Beacon Equity Issues Trading Outlook for BioElectronics Corp.
GlobeNewswire
posted: 2 HOURS 8 MINUTES AGO
DALLAS, July 24, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring drug-three patch therapies maker BioElectronics Corp. (Pink Sheets:BIEL). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.
The investment report on BioElectronics Corp. (Pink Sheets:BIEL) should be of particular interest to other healthcare-related companies: ICU Medical Inc. (Nasdaq:ICUI), Bio-Matrix Scientific Group Inc. (OTCBB:BMSN), AngioDynamics Inc. (Nasdaq:ANGO) and SenoRX Inc. (Nasdaq:SENO).
It is available at: http://www.beaconequity.com/i/BIEL
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
BioElectronics Corp. develops and markets drug-free, anti-inflammatory patch therapies to treat a variety of medical conditions. Sold under the ActiPatch Therapy name, the patch delivers pulsed electromagnetic field therapy to affect pain relief from inflamed areas of the body. Through its miniaturized microchip, power source and antenna, the ActiPatch Therapy product delivers a pulsed radio frequency signal of 27 megahertz (MHz) into the body's affected area to induce a low frequency electromagnetic field to damaged tissue cells.
In the report, the analyst notes:
"The Company's strength comes from the weakness in the top three over-the-counter drugs acetaminophen (Tylenol) made by Johnson & Johnson, Bayer's acetylsalicylic acid (Aspirin), and ibuprofen (Advil) made by Wyeth.
"The Company has upgraded its product, ironed-out product issues by moving its manufacturing to China, and expanded its distribution relationships worldwide. With overhead low, gross margins anticipated to reach 75%, according to BIEL chairman of the board, Rick Anderson, and almost no debt, the Company is poised to be profitable following FDA approvals and widespread public acceptance, according to Anderson."
To read the entire report visit: http://www.beaconequity.com/i/BIEL
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
EVFL has news
Evolution Fuels Announces New Website
10:42a ET July 23, 2009 (GlobeNewswire)
Evolution Fuels, Inc. (Pink Sheets:EVFL) (the "Company") today announced that it has completed construction of its new website. The new site contains a blog and current information regarding the Company. The website is www.evolution-fuels.com
BIEL has 3 news releases
BiomedReports: News and FDA Updates for Novavax (Nasdaq:NVAX), Transcept(Nasdaq:TSPT), Generex (Nasdaq:GNBT), BioElectronics (OTC:BIEL)
http://www.tradingmarkets.com/.site/news/Stock%20News/2437606/
InvestSource, Inc.: BioElectronics Plans Conference Call to Discuss Latest Developments Thu. July 23, 2009; Posted: 06:03 AM
Skymark Research Initiates Complimentary Research Coverage On BioElectronics Corporation 2009-07-23 09:30 ET - News Release
http://www.stockwatch.com/newsit/newsit_newsit.aspx?bid=U-z0169639-U:BIEL-20090723&symbol=BIEL&news_region=U
Thank you again auctiondude100 for your “visionary perspective”. I agree with you. I think along the way we will see that many manipulative forces are scheming together, like the “pump and dumps” always trying to panic us into a stampede to buy or a stampede for the door. Nice way to pickup cheep and sell high. If you have enough $ you can flip all day. I guess most will take advantage of a cheep pick-up, me included, but I won’t sell cheep! That’s a big problem for me, I need to learn to let go sooner. If I could just distinguish the handwriting on the wall in real time. I imagine I’m not alone wanting a decoder. It just bugs me when I see this manipulative forces push down a stock that has merit and I OWN!!!! Just Venting.
Thank you auctiondude100 any insight on our future holdings?
I know I should and will call AMERITRADE because they canceled my sell order for LFBG. What does the new symbol LFBGE mean???? What is the "E" for? Did LFBG to LFBGE? Also any news, is it good or bad?
The SPNG doom gang has done there work well, like cattle rustlers coming in from all sides. Pick out the weak and drive them out, pushing the price down on a good stock. Now we have ARTIFICIAL RESISTANCES levels to work back up through. The stock will be back in the light short or long-term, so hold, don’t sell out cheap! Your just making the doom gang richer!